Identification of Mutations Related to Cisplatin-Resistance and Prognosis of Patients With Lung Adenocarcinoma

Rui Li,Junfang Liu,Zekui Fang,Zhenyu Liang,Xin Chen

DOI: https://doi.org/10.3389/fphar.2020.572627

IF: 5.6

2020-10-29

Frontiers in Pharmacology

Abstract:Background: Lung adenocarcinoma (LUAD) is the most common histologic type of non-small cell lung cancer (NSCLC; approximately 60%), and platinum-based chemotherapy is the cornerstone of the treatment for patients with LUAD. However, a considerable number of patients experience tumor recurrence after developing cisplatin (cis-diamminedichloroplatinum(II) or CDDP) resistance. Therefore, it is particularly important to screen primary CDDP-resistant LUAD patient populations, which can maximize the clinical benefits for these patients.Methods: Data for 61 LUAD cell lines were downloaded from the Genomics of Drug Sensitivity in Cancer (GDSC) database to screen for mutations related to CDDP susceptibility, and we conducted whole-exome sequencing (WES) of tumors from 45 LUAD patients from Zhujiang Hospital of Southern Medical University. Subsequently, the clinical prognostic value of these mutations was verified by using The Cancer Genome Atlas (TCGA)-LUAD cohort and our cohort (n = 45).Results: Based on drug sensitivity data for the GDSC-LUAD cell lines and survival analysis of the cohorts TCGA-LUAD and Local-LUAD, we found only one gene (GREB1) with mutations related to decreased CDDP sensitivity as well as worse overall survival (OS) and progression-free survival (PFS) [OS: log-rank p = 0.038, hazard ratio (HR; 95% confidence interval (95% CI)): 2.19 (0.73–6.55); PFS: log-rank p = 0.001; HR: 4.65, 95% CI: 1.18–18.37]. The GREB1-mutant (GREB1-MT) group had a higher frequency of gene mutations. Additionally, gene set enrichment analysis (GSEA) and single-sample GSEA (ssGSEA) suggested reduced accumulation of intracellular drugs in the GREB1-MT group, in addition to increased drug efflux and enhanced DNA damage repair and intracellular detoxification.Conclusion: This study found that GREB1 mutations may mediate the primary resistance and clinical prognosis of LUAD patients undergoing treatment with CDDP. Further functional analysis showed that GREB1 mutations are related to the known mechanism of CDDP resistance. These results suggest that GREB1 mutations are potential biomarkers for screening of CDDP resistance among LUAD patients.

pharmacology & pharmacy

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to identify gene mutations related to cisplatin (Cisplatin, CDDP) resistance and the prognosis of patients with lung adenocarcinoma (Lung Adenocarcinoma, LUAD). Specifically, the study aims to screen out gene mutations that are associated with reduced sensitivity to CDDP and are related to poorer overall survival (Overall Survival, OS) and progression - free survival (Progression - Free Survival, PFS) in LUAD patients, in order to provide potential biomarkers for clinical diagnosis and treatment. ### Background - Lung adenocarcinoma is the most common histological type in non - small cell lung cancer (Non - Small Cell Lung Cancer, NSCLC), accounting for approximately 60%. - Platinum - based chemotherapy is the standard treatment method for LUAD patients. - However, many patients will experience tumor recurrence after developing cisplatin resistance. Therefore, it is particularly important to screen out the LUAD patient population with primary CDDP resistance, which can maximize the clinical benefits of these patients. ### Methods - Data of 61 LUAD cell lines were downloaded from the Genomics of Drug Sensitivity in Cancer (GDSC) database to screen for mutations related to CDDP sensitivity. - Whole - exome sequencing (Whole - Exome Sequencing, WES) was performed on tumors of 45 LUAD patients in Zhujiang Hospital of Southern Medical University. - The clinical prognostic value of these mutations was verified using The Cancer Genome Atlas (TCGA) - LUAD cohort and the local cohort (n = 45). ### Results - Based on the drug sensitivity data of GDSC - LUAD cell lines and the survival analysis of TCGA - LUAD and Local - LUAD cohorts, it was found that only the mutation of one gene (GREB1) was associated with reduced CDDP sensitivity and poorer OS and PFS. - OS: log - rank p = 0.038, hazard ratio (Hazard Ratio, HR) and its 95% confidence interval (95% Confidence Interval, 95% CI): 2.19 (0.73 – 6.55) - PFS: log - rank p = 0.001, HR: 4.65, 95% CI: 1.18 – 18.37 - The gene mutation frequency was higher in the GREB1 - mutant group (GREB1 - MT). - Gene set enrichment analysis (Gene Set Enrichment Analysis, GSEA) and single - sample GSEA (Single - Sample GSEA, ssGSEA) indicated that in the GREB1 - MT group, intracellular drug accumulation decreased, drug efflux increased, and DNA damage repair and intracellular detoxification capabilities enhanced. ### Conclusions - This study found that GREB1 mutation may mediate primary resistance to CDDP and poor clinical prognosis in LUAD patients. - Further functional analysis showed that GREB1 mutation was related to the known CDDP resistance mechanisms. - These results indicate that GREB1 mutation is a potential biomarker for screening CDDP resistance in LUAD patients.

Identification of Mutations Related to Cisplatin-Resistance and Prognosis of Patients With Lung Adenocarcinoma

Mutational Landscape of Cfdna Identifies Distinct Molecular Features Associated with Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.

DNAH10 mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer.

The Genomic Signature of Resistance to Platinum-Containing Neoadjuvant Therapy Based on Single-Cell Data

Drug resistance related genes in lung adenocarcinoma predict patient prognosis and influence the tumor microenvironment

Association of MDR1 and ERCC1 Polymorphisms with Response and Toxicity to Cisplatin-Based Chemotherapy in Non-Small-cell Lung Cancer Patients.

miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways

Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival

Transcriptome Sequencing Reveals Key Pathways And Genes Associated With Cisplatin Resistance In Lung Adenocarcinoma A549 Cells

Integrated Analysis of DNA Methylation and Mrna Expression Profiling Reveals Candidate Genes Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer.

Applications of Machine Learning to Predict Cisplatin Resistance in Lung Cancer

ADGRG1 Is a Predictor of Chemoresistance and Poor Survival in Cervical Squamous Carcinoma

Comprehensive analyses of Disulfidptosis-related genes on prognosis and immune infiltration in lung adenocarcinoma

WDHD1 Leads to Cisplatin Resistance by Promoting MAPRE2 Ubiquitination in Lung Adenocarcinoma

Human RECQL5 promotes metastasis and resistance to cisplatin in non-small cell lung cancer

Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches

Identification of the key DNA damage response genes for predicting immunotherapy and chemotherapy efficacy in lung adenocarcinoma based on bulk, single-cell RNA sequencing, and spatial transcriptomics

Expression patterns of platinum resistance-related genes in lung adenocarcinoma and related clinical value models

Integrative PDGF/PDGFR and focal adhesion pathways are downregulated in ERCC1-defective non-small cell lung cancer undergoing sodium glycididazole-sensitized cisplatin treatment

The role of molecular subtypes and immune infiltration characteristics based on disulfidptosis-associated genes in lung adenocarcinoma

The Identification of a Two-Gene Prognostic Model Based on Cisplatin Resistance-Related Cerna Network in Small Cell Lung Cancer.